Linssen PC - Search Results

1

Cellular and plasma adriamycin concentrations in long-term infusion therapy of leukemia patients.

Speth PA, Linssen PC, Boezeman JB, Wessels HM, Haanen C. Speth PA, et al. Among authors: linssen pc. Cancer Chemother Pharmacol. 1987;20(4):305-10. doi: 10.1007/BF00262581. Cancer Chemother Pharmacol. 1987. PMID: 3480081

2

Infusion-rate independent cellular adriamycin concentrations and cytotoxicity to human bone marrow clonogenic cells (CFU-GM).

Raijmakers R, Speth P, de Witte T, Linssen P, Wessels J, Haanen C. Raijmakers R, et al. Br J Cancer. 1987 Aug;56(2):123-6. doi: 10.1038/bjc.1987.168. Br J Cancer. 1987. PMID: 3663464 Free PMC article.

3

In vivo and in vitro pharmacokinetic differences between four structurally closely related anthracyclines in hematopoietic cell subtypes in humans.

Speth PA, Linssen PC, Termond EF, Boezeman JB, Wessels HM, Haanen C. Speth PA, et al. Among authors: linssen pc. Drug Metab Dispos. 1989 Jan-Feb;17(1):98-105. Drug Metab Dispos. 1989. PMID: 2566478

4

Phase I and pharmacokinetic studies with the pentacyclic pyrroloquinone mitoquidone.

Speth PA, Gore ME, Pateman AJ, Newell DR, Bishop JA, Ellis WJ, Green JA, Gumbrell LA, Linssen PC, Miller A, et al. Speth PA, et al. Among authors: linssen pc. Cancer Chemother Pharmacol. 1988;21(4):343-6. doi: 10.1007/BF00264202. Cancer Chemother Pharmacol. 1988. PMID: 3370744

5

In vivo cellular adriamycin concentrations related to growth inhibition of normal and leukemic human bone marrow cells.

Speth PA, Raijmakers RA, Boezeman JB, Linssen PC, de Witte TJ, Wessels HM, Haanen C. Speth PA, et al. Among authors: linssen pc. Eur J Cancer Clin Oncol. 1988 Apr;24(4):667-74. doi: 10.1016/0277-5379(88)90297-0. Eur J Cancer Clin Oncol. 1988. PMID: 3383969

6

Cellular and plasma pharmacokinetics of weekly 20-mg 4'-epi-adriamycin bolus injection in patients with advanced breast carcinoma.

Speth PA, Linssen PC, Beex LV, Boezeman JB, Haanen C. Speth PA, et al. Among authors: linssen pc. Cancer Chemother Pharmacol. 1986;18(1):78-82. doi: 10.1007/BF00253070. Cancer Chemother Pharmacol. 1986. PMID: 3463436

7

Plasma and cellular adriamycin concentrations in patients with myeloma treated with ninety-six-hour continuous infusion.

Speth PA, Linssen PC, Holdrinet RS, Haanen C. Speth PA, et al. Among authors: linssen pc. Clin Pharmacol Ther. 1987 Jun;41(6):661-5. doi: 10.1038/clpt.1987.92. Clin Pharmacol Ther. 1987. PMID: 3581649

8

Leukemic cell and plasma daunomycin concentrations after bolus injection and 72 h infusion.

Speth PA, Linssen PC, Boezeman JB, Wessels HM, Haanen C. Speth PA, et al. Among authors: linssen pc. Cancer Chemother Pharmacol. 1987;20(4):311-5. doi: 10.1007/BF00262582. Cancer Chemother Pharmacol. 1987. PMID: 3690804

9

Toxicity of idarubicin and doxorubicin towards normal and leukemic human bone marrow progenitors in relation to their proliferative state.

Minderman H, Linssen P, van der Lely N, Wessels J, Boezeman J, de Witte T, Haanen C. Minderman H, et al. Leukemia. 1994 Mar;8(3):382-7. Leukemia. 1994. PMID: 8127143

10

Cell cycle related uptake, retention and toxicity of idarubicin, daunorubicin and doxorubicin.

Minderman H, Linssen P, Wessels J, Haanen C. Minderman H, et al. Anticancer Res. 1993 Jul-Aug;13(4):1161-5. Anticancer Res. 1993. PMID: 8352539

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

43 results

Search Page

Filters